We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer.
- Authors
Tajima, Hidehiro; Okazaki, Mitsuyoshi; Yamaguchi, Takahisa; Ohbatake, Yoshinao; Okamoto, Koichi; Nakanuma, Shinichi; Terai, Shiro; Sakai, Seisho; Kinoshita, Jun; Makino, Isamu; Nakamura, Keishi; Hayashi, Hironori; Oyama, Katsunobu; Inokuchi, Masafumi; Miyashita, Tomoharu; Takamura, Hiroyuki; Ninomiya, Itasu; Fushida, Sachio; Ohta, Tetsuo
- Abstract
The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The present study conducted a Phase I clinical trial of weekly low-dose PTX as a third-line palliative chemotherapy for patients with pancreatic cancer. PTX was administered on days 1, 8, 15, and 22 of each cycle, repeated twice as follows: Level 1, 40 mg/m2 (n=6); Level 2, 50 mg/m2 (n=4). During the two cycles, three patients developed Grade 3 neutropenia in level 2; thus, the recommended dose was defined as 40 mg/m2. The disease control rate was 40.0% (stable disease, n=4). Median time to treatment failure of the four patients with stable disease was 5.5 months. In conclusion, palliative chemotherapy with low-dose PTX after failure of GEM and 5-FU is well tolerated and safe for unresectable or recurrent pancreatic cancer patients. The unique ID issues by UMIN: 000008148.
- Subjects
PANCREATIC cancer treatment; PACLITAXEL; CANCER chemotherapy
- Publication
Molecular & Clinical Oncology, 2018, Vol 8, Issue 4, p623
- ISSN
2049-9450
- Publication type
Article
- DOI
10.3892/mco.2018.1579